Paradigm Biocapital Advisors LP Syndax Pharmaceuticals Inc Transaction History

Paradigm Biocapital Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $494,478 - $741,377	-34,055 Reduced 1.4%	2,390,077 $34.7 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $2.9 Million - $3.34 Million	149,620 Added 6.58%	2,424,132 $50.7 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $6.61 Million - $9.27 Million	320,000 Added 16.37%	2,274,512 $48 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $17.9 Million - $22.8 Million	869,370 Added 80.12%	1,954,512 $49.7 Million
Q3 2022 Nov 14, 2022	BUY	$18.51 - $24.79 $3.87 Million - $5.18 Million	208,986 Added 23.85%	1,085,142 $26.1 Million
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $2.38 Million - $3.41 Million	174,800 Added 24.92%	876,156 $16.9 Million
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $3.68 Million - $5.5 Million	248,265 Added 54.79%	701,356 $12.2 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $6.9 Million - $10.2 Million	453,091 New	453,091 $9.92 Million

231

90M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $792M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.